Other PM-related Initiatives & Consortia

Initiatives with close collaboration

ICPerMed & ICPerMed Family

The International Consortium for Personalsied Medicine (ICPerMed) provides a platform to initiate and support communication and exchange on personalised medicine research, funding and implementation. The high level of participation from all over Europe and beyond enables ICPerMed to efficiently map the scientific and political landscape. ICPerMed works in close collaboration with the European Research Area Network for Personalised Medicine (ERA PerMed), several Coordination and Support Actions (CSAs) funded by the European Commission, as well as with an increasing number of associated and related initiatives, research infrastructures and capacities. This so called ICPerMed ‘Family’ has an important role in supporting the research and implementation of personalised medicine in Europe and beyond.

ERA PerMed – ERA-Net Cofund in Personalised Medicine

ERA PerMed was a new ERA-Net Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in PM, and enhance the European collaboration with non-EU countries, national funding organisations have agreed to launch Joint Transnational Calls for collaborative innovative research projects in Personalised Medicine (PM).

1+ Million Genomes Framework

The 1+ Million Genomes (1+MG) initiative aims to enable secure access to genomics and the corresponding clinical data across Europe for better research, personalised healthcare and health policy making. Since the Digital Day 2018, 24 EU countries plus the United Kingdom and Norway signed the Member States’ Declaration ‘Towards access to at least 1 million sequenced genomes in the EU by 2022.

The Beyond 1 Million Genomes (B1MG) project is helping to create a network of genetic and clinical data across Europe. The project provides coordination and support to the 1+ Million Genomes Initiative (1+MG). This initiative is a commitment of 24 EU countries, the UK and Norway to give cross-border access to one million sequenced genomes by 2022. But B1MG will go ‘beyond’ the 1+MG Initiative by creating long-term means of sharing data beyond 2022, and enabling access to beyond 1 million genomes.

The Genomic Data Infrastructure (GDI) project is enabling access to genomic and related phenotypic and clinical data across Europe. It is doing this by establishing a federated, sustainable and secure infrastructure to access the data. It builds on the outputs of the Beyond 1 Million Genomes (B1MG) project and is realising the ambition of the 1+Million Genomes (1+MG) initiative.

European Partnerships

Innovative Health Initiative (IHI)

The Innovative Health Initiative is an EU public-private partnership funding health research and innovation. By leveraging the skills of a range of scientific fields – from pharmaceuticals and biotechnology to medical technology and big data – IHI funds projects that will address public health needs, improve patients’ lives, and boost the competitiveness of Europe’s health industries. IHIs core goals are to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.

European Partnership on Transforming Health and Care Systems (THCS)

Health and care systems in Europe are facing core common challenges, which require harmonised and coordinated solutions. The European Partnership on Transforming Health and Care Systems (THCS) represents a unique strategic opportunity to bring together stakeholders, create synergies, coordinate Research and Innovation actions, facilitate the digitization of health and care services and support the transformation of health and care systems with innovative solutions driven by knowledge and evidence.

The general objective of THCS is to contribute to the transition towards more sustainable, efficient, resilient, inclusive, innovative and high-quality people-centred health and care systems equally accessible to all people.

Era4Health Partnership

The ERA4Health Partnership brings together 33 partners and 27 funding  organisations from 22 countries, with the common goal of fostering high-impact translational research for addressing public health needs.

Through cross-national joint calls for proposals, other cross-cutting activities and an optimal use of and making the most of interregional and international cooperation, ERA4Health aims to provide influential contributions as well as a sustainable model of funding for ground-breaking translational research in the health domain across Europe and beyond.

EJP Rare Diseases / The European Rare Diseases Research Alliance (ERDERA)

The European Joint Programme on Rare Diseases (EJP RD) is a programme aiming to create an effective rare diseases research ecosystem for progress, innovation and for the benefit of everyone with a rare disease. We support rare diseases stakeholders by funding research, bringing together data resources & tools, providing dedicated training courses, and translating high quality research into effective treatments.

The proposal for the EJP Rare Diseases successor European Rare Diseases Research Alliance (ERDERA) proposal was submitted under Horizon Europe on 19 Sept. 2023 for funding as a co-funded European Partnership. ERDERA has the ambition to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in RD research and innovation, to support concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment.

European & Developing Countries Clinical Trials Partnership (EDCTP)

EDCTP’s vision is to reduce the individual, social and economic burden of poverty-related infectious diseases in sub-Saharan Africa, by supporting collaborative research to develop accessible, suitable and affordable medical interventions.

EDCTP’s mission is to enhance research capacity and accelerate the development of new or improved medical interventions for the identification, treatment and prevention of poverty-related infectious diseases, including emerging and re-emerging diseases in sub-Saharan Africa, through all phases of clinical trials, with emphasis on phase II and III trials.

Other related Iniatives

TRANSCAN – ERA-NET: Sustained collaboration of national and regional programmes in cancer research

The EU-funded TRANSCAN-3 project is bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research. Through cross-national joint calls for proposals and making the most of international and interregional cooperation, TRANSCAN-3 aims to provide influential contributions as well as a sustainable model of funding for ground-breaking translational cancer research in Europe and beyond.


Research into the diseases of the brain benefits from joint funding schemes by networks of funding agencies and ministries in Europe and beyond the European borders. The ERA-Net NEURON Cofund2, as a funding platform focused on neurological and mental disorders, holds a strategic position in bringing pre-clinical and clinical research communities closer together and fostering translational research, while covering the entire value chain.

Joint Programme – Neurodegenerative Disease Research (JPND)

JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases. The ultimate goal of JPND is to find cures for neurodegenerative diseases and to enable early diagnosis for early targeted treatments. However, it is not possible to give definitive predictions on how long this might take to happen.